Can I read 2026 Nasal Spray Approved For Supraventricular Tachycardia - NEJM Clinician on EtoBox?
2026 Nasal Spray Approved For Supraventricular Tachycardia - NEJM Clinician by MohanKumarHanumanthappa is a document available to read on EtoBox.
What is 2026 Nasal Spray Approved For Supraventricular Tachycardia - NEJM Clinician about?
The FDA has approved etripamil, a nasal spray for the outpatient treatment of supraventricular tachycardias (SVTs), allowing patients to convert to sinus rhythm without needing emergency department visits. In clinical trials, approximately two-thirds of patients using etripamil converted to sinus rhythm within 10 minutes, significantly faster than those on placebo. Etripamil is a self-administered, fast-acting calcium-channel blocker that may be a cost-effective option for managing SVT symptoms.
- Author
- MohanKumarHanumanthappa
- Language
- EN